

## Synthesis of Paclitaxel. 1. Synthesis of the ABC Ring of Paclitaxel by $\text{SmI}_2$ -Mediated Cyclization


Keisuke Fukaya,<sup>†</sup> Yuta Tanaka,<sup>†</sup> Ayako C. Sato,<sup>†</sup> Keisuke Kodama,<sup>†</sup> Hirohisa Yamazaki,<sup>†</sup> Takeru Ishimoto,<sup>†</sup> Yasuyoshi Nozaki,<sup>†</sup> Yuki M. Iwaki,<sup>†</sup> Yohei Yuki,<sup>†</sup> Kentaro Umei,<sup>†</sup> Tomoya Sugai,<sup>†</sup> Yu Yamaguchi,<sup>†</sup> Ami Watanabe,<sup>†</sup> Takeshi Oishi,<sup>‡</sup> Takaaki Sato,<sup>†</sup> and Noritaka Chida<sup>\*,†</sup>

<sup>†</sup>Department Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan

<sup>‡</sup>School of Medicine, Keio University, 4-1-1 Hiyoshi, Kohoku-ku, Yokohama 223-8521, Japan

### S Supporting Information

**ABSTRACT:** A convergent synthesis of the ABC ring of antitumor natural product paclitaxel (Taxol) is described.  $\text{SmI}_2$ -mediated reductive cyclization of an allylic benzoate possessing an aldehyde function, synthesized from tri-*O*-acetyl-*D*-glucal and 1,3-cyclohexanedione, smoothly afforded the highly strained 6–8–6 tricyclic structure in 66% yield.



Paclitaxel (Taxol, **1**) is a well-documented natural diterpenoid that has been used as an anticancer drug.<sup>1–3</sup> The challenging structure, a highly strained 6–8–6 tricyclic framework with a bridgehead olefin and an oxetane ring, as well as important biological activities of **1** have naturally attracted much attention from the synthetic community, and many studies toward the synthesis of **1** have been reported.<sup>4</sup> Although nine successful total and formal syntheses of **1** have been documented to date,<sup>5–13</sup> for the creation of novel anticancer agents, development of an efficient synthetic route to chiral **1** and its derivatives starting from readily available materials is still an important issue in the field of organic and medicinal chemistry. In this paper, we report the convergent synthesis of the ABC ring **3** of paclitaxel starting from tri-*O*-acetyl-*D*-glucal and 1,3-cyclohexanedione employing the  $\text{SmI}_2$ -mediated cyclization reaction as the key step.

Our retrosynthetic analysis of **1** based on the chiral pool approach utilizing *D*-glucal as the starting material<sup>14</sup> suggested that Takahashi's oxetane intermediate **2**<sup>12</sup> would be a suitable target molecule for the paclitaxel synthesis (Figure 1). For the preparation of **2**, the ABC ring intermediate **3** was expected to be a potential precursor. Construction of the strained 6–8–6 tricyclic structure **3** was perceived to be the most challenging issue, and we reasoned that bond formation between C10 and C11 by the  $\text{SmI}_2$ -mediated reaction<sup>15,16</sup> of allylic benzoate **4** having an aldehyde function would provide a feasible approach to **3**.<sup>17</sup>

The pioneering work of Molander<sup>18a</sup> and Matsuda<sup>18b,c</sup> has revealed that the  $\text{SmI}_2$ -mediated reductive cyclization of carbonyl compounds possessing allylic acetate or allylic chloride functionalities is a powerful reaction for the construction of eight-membered carbocycles. Their successful results, as well as previous syntheses of ABC rings of paclitaxel by a C10–C11





Figure 1. Retrosynthetic analysis of paclitaxel (**1**).

closure, suggested the possibility of our approach.<sup>18,19</sup> The substrate for the  $\text{SmI}_2$ -mediated cyclization, ABC precursor **4**, in turn was planned to be obtained by the Shapiro coupling of the A-ring hydrazone **5** with C-ring **6**.

Received: April 21, 2015

Our synthetic endeavors started with the synthesis of the C ring (Scheme 1). Treatment of optically pure cyclohexenone 7,


### Scheme 1. Synthesis of the C Ring of Paclitaxel



prepared from tri-*O*-acetyl-D-glucal,<sup>20</sup> with vinylmagnesium chloride in the presence of CuI afforded a 1,4-addition product, which was trapped with TMSCl to give a TMS enol ether. Without purification, the enol ether was treated with formalin and  $\text{Sc}(\text{OTf})_3$ <sup>21</sup> to give **8a** and **8b** in 60% and 23% isolated yields, respectively.<sup>22</sup> Protection of the primary hydroxy group in **8a** as a THP ether afforded **9** (93% yield), whose ketone carbonyl was reduced to give secondary alcohol **10** (50% yield) and its 4-epimer (50% yield).<sup>23</sup> After conversion of the secondary alcohol in **10** to a MOM ether, hydroboration–oxidation of the resulting **11** afforded primary alcohol **12** in 88% yield from **10**. Formation of the *O*-TBDPS ether, removal of the THP group, and subsequent oxidation of the resulting primary alcohol with  $\text{Pr}_4\text{NRuO}_4$  (TPAP) provided C-ring **6** in 80% yield from **12**.

Coupling of C-ring **6** with A-ring **5** was achieved by the Shapiro reaction, which had been employed for the coupling of similar A and C rings in the synthesis of paclitaxel reported by Nicolaou,<sup>6</sup> Danishefsky,<sup>7</sup> and Takahashi.<sup>12</sup> Thus, treatment of hydrazone **5**, synthesized from 1,3-cyclohexanedione in six steps,<sup>24</sup> with BuLi afforded a vinyl anion species, which was then reacted with C-ring **6** (Scheme 2). The reaction proceeded under chelation control<sup>6c</sup> to produce **13** in 92% yield as a single isomer. The hydroxy-directed epoxidation<sup>6c</sup> of **13** gave  $\beta$ -epoxide **14** as the sole product in 91% yield. Regioselective reduction of **14** with DIBAL afforded diol **15**, which was then treated with triphosgene to give cyclic carbonate **16** in 90% yield from **14**. Reaction of **16** with  $\text{CrO}_3$  in the presence of 3,5-dimethylpyrazole (3,5-DMP)<sup>25</sup> in  $\text{CH}_2\text{Cl}_2$  first oxidized a benzylic carbon to give benzoate **17** and


### Scheme 2. Preparation of the A–C Rings of Paclitaxel



then the allylic position to provide cyclohexenone **18** in 20% and 50% yields, respectively. Reoxidation of benzoate **17** under the same reaction conditions afforded an additional amount of **18** in 44% yield.

With the appropriately functionalized AC ring of paclitaxel in hand, transformation of **18** into the cyclization precursor **4** was carried out (Scheme 3). While reduction of **18** with NaBH<sub>4</sub>


### Scheme 3. Preparation of the ABC Precursor 4



afforded a mixture of allylic alcohols **19a** and **19b** (75% yield, 1.8:1), reaction with L-Selectride stereoselectively generated **19b** in 68% yield. Esterification of the allylic alcohol in **19b** with benzoic acid cleanly provided benzoate **20b** (80% yield), whose TBDPS group was removed to give **21b** in 99% yield. The structure of **21b** was unambiguously confirmed by X-ray analysis.<sup>26,27</sup> Oxidation of **21b** with Dess–Martin periodinane (DMP) furnished cyclization precursor **4b** (91% yield). The same reaction sequence was applied to **19a** to provide another precursor, epimeric benzoate **4a**, in 50% overall yield.

Next, the crucial SmI<sub>2</sub>-mediated cyclization was investigated (Scheme 4). After many attempts, it was found that when

**Scheme 4. Construction of ABC Ring of Paclitaxel 3**



compound **4b** was treated with SmI<sub>2</sub> in HMPA–THF at 40 °C, the desired reductive cyclization took place to generate the eight-membered carbocycle, ABC ring **3**, in 66% yield as an epimeric mixture (**3a**:**3b** = 1.5:1). The isomeric tricyclic **22** in which carbon–carbon bond formation occurred between C10 and C13 was also isolated in 29% yield. The structures of **3a** and **3b** were fully confirmed by X-ray analyses,<sup>27,28</sup> and the structure of **22** was assigned on the basis of <sup>1</sup>H NMR experiments. In the SmI<sub>2</sub>-mediated reaction of **4b**, the use of HMPA as a cosolvent was essential for the successful cyclization: the reaction in the absence of HMPA gave no cyclized product but afforded primary alcohol **21b**. The configuration of the allylic benzoate was also an important factor. Under the same reaction conditions as employed for **4b**, epimeric benzoate **4a** gave many unidentified products, and no cyclized product (**3** nor **22**) was detected in the reaction mixture.

Although the detailed mechanism of the cyclization reaction has been unclear so far, the reaction of **4b** would proceed via an allylic organosamarium species (Barbier-type reaction) and/or a biradical intermediate (coupling of ketyl and allylic radicals).<sup>15,29</sup> In the absence of HMPA, the less reactive SmI<sub>2</sub> did not affect the allylic benzoate but reduced only the aldehyde function.<sup>30</sup> The striking difference in the experimental results between **4a** and **4b** implied that the chelation of SmI<sub>2</sub> might be important for cyclization. In compound **4b**, having a *syn* relationship of the benzoate group at C13 and the oxygen at C1, chelation between SmI<sub>2</sub> and the C13-benzoyl/C1-oxygen would be possible, whereas epimeric **4a** would be unlikely to have a stable chelated structure due to its *anti* relationship of the C13-benzoate and the C1-oxygen. The chelation pathway in **4b** might have accelerated the rate of the reduction of the

allylic benzoate to generate an allylic radical or allylic samarium species smoothly,<sup>31</sup> which afforded eight-membered carbocycles **3** and **22** with high efficiency (95% combined yield).

In summary, the ABC ring of paclitaxel **3**, based on the chiral pool approach using tri-*O*-acetyl-D-glucal as the starting material, has been synthesized. The key SmI<sub>2</sub>-mediated reductive cyclization of allylic benzoate possessing an aldehyde function **4b** proved to be a powerful reaction for the construction of the eight-membered ring and successfully provided the highly strained 6–8–6 tricyclic **3** in 66% yield. Since compound **3** has the basic framework of paclitaxel with appropriate functionalities, it is expected to be a promising intermediate for the synthesis of paclitaxel. Efforts for conversion of **3** to paclitaxel are the subject of the following paper.<sup>4d</sup>

## ■ ASSOCIATED CONTENT

### Supporting Information

Experimental procedures; copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of new compounds; the crystallographic data of **3a**, **3b**, and **21b**. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b01173.

## ■ AUTHOR INFORMATION

### Corresponding Author

\* E-mail: chida@applc.keio.ac.jp.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This work was supported by a Grant-in Aid for Scientific Research (B) from JSPS (26288018). We thank Prof. Takeshi Noda (Kanagawa Institute of Technology, Japan) for mass spectrometric measurements. Prof. Fuyuhiko Matsuda (Hokkaido University, Japan) is gratefully acknowledged for useful discussions on SmI<sub>2</sub> chemistry. We also thank Dr. Hitoshi Tamura, Dr. Masaki Setoguchi, Dr. Takayuki Momose, Toshiki Fujita, and Shin Ashihara (Keio University) for their contributions to this project at an early stage.

## ■ REFERENCES

- (1) Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. *J. Am. Chem. Soc.* **1971**, *93*, 2325–2327.
- (2) Recent review on natural taxanes: Wang, Y.-F.; Shi, Q.-W.; Dong, M.; Kiyota, H.; Gu, Y.-C.; Cong, B. *Chem. Rev.* **2011**, *111*, 7652–7709.
- (3) Biological activities of taxanes, see: Georg, G. I.; Chen, T. T.; Ojima, I.; Vyas, D. M., Eds.; ACS Symp. Ser. 583; American Chemical Society: Washington, DC, 1994.
- (4) Reviews on synthetic study of paclitaxel and related compounds: (a) Nicolaou, K. C.; Dai, W.-M.; Guy, R. K. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 15–44. (b) Kingston, D. G. I. *Chem. Commun.* **2001**, 867–880. (c) Ishihara, Y.; Mendoza, A.; Baran, P. S. *Tetrahedron* **2013**, *69*, 5685–5701. (d) For recent synthetic studies, see ref 3 in the following paper: Fukaya, K.; Kodama, K.; Tanaka, Y.; Yamazaki, H.; Sugai, T.; Yamaguchi, Y.; Watanabe, A.; Oishi, T.; Sato, T.; Chida, N. *Org. Lett.* **2015**, DOI: 10.1021/acs.orglett.5b01174.
- (5) (a) Holton, R. A.; Somoza, C.; Kim, H.-B.; Liang, F.; Biediger, R. J.; Boatman, P. D.; Shindo, M.; Smith, C. C.; Kim, S.; Nadizadeh, H.; Suzuki, Y.; Tao, C.; Vu, P.; Tang, S.; Zhang, P.; Murthi, K. K.; Gentile, L. N.; Liu, J. H. *J. Am. Chem. Soc.* **1994**, *116*, 1597–1598. (b) Holton, R. A.; Kim, H.-B.; Somoza, C.; Liang, F.; Biediger, R. J.; Boatman, P. D.; Shindo, M.; Smith, C. C.; Kim, S.; Nadizadeh, H.; Suzuki, Y.; Tao,



- C.; Vu, P.; Tang, S.; Zhang, P.; Murthi, K. K.; Gentile, L. N.; Liu, J. H. *J. Am. Chem. Soc.* **1994**, *116*, 1599–1600.
- (6) (a) Nicolaou, K. C.; Yang, Z.; Liu, J. J.; Ueno, H.; Nantermet, P. G.; Guy, R. K.; Claiborne, C. F.; Renaud, J.; Couladouros, E. A.; Paulvannan, K.; Sorensen, E. J. *Nature* **1994**, *367*, 630–634. (b) Nicolaou, K. C.; Nantermet, P. G.; Ueno, H.; Guy, R. K.; Couladouros, E. A.; Sorensen, E. J. *J. Am. Chem. Soc.* **1995**, *117*, 624–633. (c) Nicolaou, K. C.; Liu, J.-J.; Yang, Z.; Ueno, H.; Sorensen, E. J.; Claiborne, C. F.; Guy, R. K.; Hwang, C.-K.; Nakada, M.; Nantermet, P. G. *J. Am. Chem. Soc.* **1995**, *117*, 634–644. (d) Nicolaou, K. C.; Yang, Z.; Liu, J.-J.; Nantermet, P. G.; Claiborne, C. F.; Renaud, J.; Guy, R. K.; Shibayama, K. *J. Am. Chem. Soc.* **1995**, *117*, 645–652. (e) Nicolaou, K. C.; Ueno, H.; Liu, J.-J.; Nantermet, P. G.; Yang, Z.; Renaud, J.; Paulvannan, K.; Chadha, R. *J. Am. Chem. Soc.* **1995**, *117*, 653–659.
- (7) (a) Masters, J. J.; Link, J. T.; Snyder, L. B.; Young, W. B.; Danishefsky, S. J. *Angew. Chem., Int. Ed. Engl.* **1995**, *34*, 1723–1726. (b) Danishefsky, S. J.; Masters, J. J.; Young, W. B.; Link, J. T.; Snyder, L. B.; Magee, T. V.; Jung, D. K.; Isaacs, R. C. A.; Bornmann, W. G.; Alaimo, C. A.; Coburn, C. A.; Grandi, M. J. D. *J. Am. Chem. Soc.* **1996**, *118*, 2843–2859.
- (8) (a) Wender, P. A.; Badham, N. F.; Conway, S. P.; Floreancig, P. E.; Glass, T. E.; Gränicher, C.; Houze, J. B.; Jänichen, J.; Lee, D.; Marquess, D. G.; McGrane, P. L.; Meng, W.; Mucciari, T. P.; Mühlebach, M.; Natchus, M. G.; Paulsen, H.; Rawlins, D. B.; Satkofsky, J.; Shuker, A. J.; Sutton, J. C.; Taylor, R. E.; Tomooka, K. *J. Am. Chem. Soc.* **1997**, *119*, 2755–2756. (b) Wender, P. A.; Badham, N. F.; Conway, S. P.; Floreancig, P. E.; Glass, T. E.; Houze, J. B.; Krauss, N. E.; Lee, D.; Marquess, D. G.; McGrane, P. L.; Meng, W.; Natchus, M. G.; Shuker, A. J.; Sutton, J. C.; Taylor, R. E. *J. Am. Chem. Soc.* **1997**, *119*, 2757–2758.
- (9) (a) Mukaiyama, T.; Shiina, I.; Iwadare, H.; Sakoh, H.; Tani, Y.; Hasegawa, M.; Saitoh, K. *Proc. Jpn. Acad., Ser. B* **1997**, *73*, 95–100. (b) Shiina, I.; Iwadare, H.; Sakoh, H.; Hasegawa, M.; Tani, Y.; Mukaiyama, T. *Chem. Lett.* **1998**, 1–2. (c) Shiina, I.; Saitoh, K.; Frécharde-Ortuno, I.; Mukaiyama, T. *Chem. Lett.* **1998**, 3–4. (d) Mukaiyama, T.; Shiina, I.; Iwadare, H.; Saitoh, M.; Nishimura, T.; Ohkawa, N.; Sakoh, H.; Nishimura, K.; Tani, Y.; Hasegawa, M.; Yamada, K.; Saitoh, K. *Chem.—Eur. J.* **1999**, *5*, 121–161.
- (10) (a) Morihira, K.; Hara, R.; Kawahara, S.; Nishimori, T.; Nakamura, N.; Kusama, H.; Kuwajima, I. *J. Am. Chem. Soc.* **1998**, *120*, 12980–12981. (b) Kusama, H.; Hara, R.; Kawahara, S.; Nishimori, T.; Kashima, H.; Nakamura, N.; Morihira, K.; Kuwajima, I. *J. Am. Chem. Soc.* **2000**, *122*, 3811–3820.
- (11) Lim, J. Ph.D. Dissertation, Harvard University, Cambridge, MA, 2000.
- (12) Doi, T.; Fuse, S.; Miyamoto, S.; Nakai, K.; Sasuga, D.; Takahashi, T. *Chem.—Asian J.* **2006**, *1*, 370–383.
- (13) Hirai, S.; Utsugi, M.; Iwamoto, M.; Nakada, M. *Chem.—Eur. J.* **2015**, *21*, 355–359.
- (14) (a) Chida, N.; Sato, T. In *Comprehensive Chirality*; Carreira, E. M., Yamamoto, H., Eds.; Elsevier: Amsterdam, 2012; Vol. 2, pp 207–239. (b) Chida, N.; Sato, T. *Chem. Rec.* **2014**, *14*, 592–605.
- (15) For a comprehensive review on SmI<sub>2</sub> chemistry, see: Procter, D. A.; Flowers, R. A., II; Skrydstrup, T. *Organic Synthesis Using Samarium Diodide*; The Royal Society of Chemistry: Cambridge, 2010.
- (16) Reviews on SmI<sub>2</sub>-mediated reactions in natural product synthesis: (a) Edmonds, D. J.; Johnston, D.; Procter, D. J. *Chem. Rev.* **2004**, *104*, 3371–3403. (b) Nicolaou, K. C.; Ellery, S. P.; Chen, J. S. *Angew. Chem., Int. Ed.* **2009**, *48*, 7140–7165.
- (17) It has been reported that the reaction of allyl benzoate and allyl toluate with SmI<sub>2</sub> in THF–HMPA smoothly generated an allyl radical or allyl samarium species. The Barbier-type reaction of allyl toluate with ketones by the action of SmI<sub>2</sub>–HMPA has also been reported; see: Lam, K.; Markó, I. E. *Tetrahedron* **2009**, *65*, 10930–10940.
- (18) (a) Molander, G. A.; McKie, J. A. *J. Org. Chem.* **1994**, *59*, 3186–3192. (b) Matsuda, F.; Sakai, T.; Okada, N.; Miyashita, M. *Tetrahedron Lett.* **1998**, *39*, 863–864. (c) Tamiya, H.; Goto, K.; Matsuda, F. *Org. Lett.* **2004**, *6*, 545–547.
- (19) The construction of the ABC ring by the bond formation between C10 and C11 has been reported by Danishefsky (Heck reaction, ref 7), Kishi and Lim (Nozaki–Hiyama–Kishi reaction, ref 11), and Nakada (Pd-catalyzed alkenylation, ref 13) in their successful synthesis of paclitaxel.
- (20) Momose, T.; Setoguchi, M.; Fujita, T.; Tamura, H.; Chida, N. *Chem. Commun.* **2000**, 2237–2238.
- (21) Kobayashi, S.; Hachiya, I.; Ishitani, H.; Araki, M. *Synlett* **1993**, 472–474.
- (22) Base-induced epimerization of **8b** (K<sub>2</sub>CO<sub>3</sub>, MeOH) gave an additional amount of desired **8a** (31% yield, **8b** was recovered in 55% yield).
- (23) Oxidation of the undesired 4-epimer with TPAP regenerated ketone **9** in 77% yield.
- (24) Compound **5** was synthesized according to the method reported by Koskinen with some modifications; see: Törmäkangas, O. P.; Toivola, R. J.; Karvinen, E. K.; Koskinen, A. M. P. *Tetrahedron* **2002**, *58*, 2175–2181. For details, see the Supporting Information.
- (25) (a) Salmond, W. G.; Barta, M. A.; Havens, J. L. *J. Org. Chem.* **1978**, *43*, 2057–2059. (b) Kende, A. S.; Johnson, S.; Sanfilippo, P.; Hodges, J. C.; Jungheim, L. N. *J. Am. Chem. Soc.* **1986**, *108*, 3513–3515.
- (26) Oishi, T.; Yamaguchi, Y.; Fukaya, K.; Sugai, T.; Watanabe, A.; Sato, T.; Chida, N. *Acta Crystallogr.* **2015**, *E71*, 8–11.
- (27) The X-ray analyses were performed with racemic samples. The racemic compounds were synthesized from racemic **7**, which was prepared from 3-methoxytoluene in four reaction steps by the procedure reported by Frejd; see: Polla, M.; Frejd, T. *Tetrahedron* **1991**, *47*, 5883–5894.
- (28) Oishi, T.; Fukaya, K.; Yamaguchi, Y.; Sugai, T.; Watanabe, A.; Sato, T.; Chida, N. *Acta Crystallogr.* **2015**, *E71*, 466–472.
- (29) Recent review on SmI<sub>2</sub>-mediated reactions containing intramolecular Barbier type reactions: Szostak, M.; Fazakerley, N. J.; Parmar, D.; Procter, D. J. *Chem. Rev.* **2014**, *114*, 5959–6039.
- (30) It is well-known that HMPA dramatically increases the reduction potential of SmI<sub>2</sub>; see: (a) Shabangi, M.; Flowers, R. A., II. *Tetrahedron Lett.* **1997**, *38*, 1137–1140. (b) Flowers, R. A., II. *Synlett* **2008**, 1427–1439.
- (31) The chelation of SmI<sub>2</sub> with oxygen functions is reported to accelerate the rate of reduction of ketones, and it is reported that the chelation occurs to some extent even in the presence of HMPA. see: (a) Prasad, E.; Flowers, R. A., II. *J. Am. Chem. Soc.* **2002**, *124*, 6357–6361. (b) Prasad, E.; Flowers, R. A., II. *J. Am. Chem. Soc.* **2002**, *124*, 6895–6899.